newsfilter
← Latest News
GlobeNewswire·

Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property

Last patient last visit complete in SPL026 Phase IIa clinical trial with topline results expected early in Q1 European patent granted for synthetic manufacturing process of key pipeline candidates LONDON,